A methodological framework for meta-analysis and clinical interpretation of subgroup data: the case of major adverse cardiovascular events with GLP-1 receptor …
We present a methodological framework for conducting and interpreting subgroup meta-
analyses. Methodological steps comprised evaluation of clinical heterogeneity regarding the …
analyses. Methodological steps comprised evaluation of clinical heterogeneity regarding the …
EVOO's Effects on Incretin Production: Is There a Rationale for a Combination in T2DM Therapy?
S Amodeo, L Mirarchi, A Seidita, R Citarrella… - International Journal of …, 2022 - mdpi.com
Type 2 diabetes mellitus (T2DM) is a serious public health concern as it is one of the most
common chronic diseases worldwide due to social and economic developments that have …
common chronic diseases worldwide due to social and economic developments that have …
Antidiabetic Molecule Efficacy in Patients with Type 2 Diabetes Mellitus—A Real-Life Clinical Practice Study
In this paper, we aim to evaluate the efficacy of antidiabetic cardioprotective molecules such
as Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) and Glucagon-like Peptide 1 …
as Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) and Glucagon-like Peptide 1 …
The Reasons for the Low Uptake of New Antidiabetic Drugs with Cardiovascular Effects—A Family Doctor Perspective
T Kurevija, D Šojat, Z Bosnić, B Mujaj… - Journal of Clinical …, 2024 - mdpi.com
Chronic diseases, such as type 2 diabetes (T2D), are difficult to manage because they
demand continuous therapeutic review and monitoring. Beyond achieving the target HbA1c …
demand continuous therapeutic review and monitoring. Beyond achieving the target HbA1c …
Olive oil, fruit and leaves in diabetes mellitus type 2 treatment
M Nosić, VY Waisundara… - Exploration of foods and …, 2023 - explorationpub.com
The Mediterranean dietary pattern, where extra virgin olive oil (EVOO) takes the central spot,
is related to longer life expectancy and lower risk of a number of non-communicable …
is related to longer life expectancy and lower risk of a number of non-communicable …
[HTML][HTML] HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity
PP Mohanan, P Jariwala - Indian Heart Journal, 2023 - Elsevier
Diabetes is a common condition with a dismal prognosis. According to the International
Diabetes Federation, 537 million people worldwide have diabetes. Cardiovascular disorders …
Diabetes Federation, 537 million people worldwide have diabetes. Cardiovascular disorders …
The Reasons for Low Uptake of New Antidiabetic Drugs with Cardiovascular Effects–a Family Doctor Perspective: Does Limited Applicability of Clinical Guidelines in …
T Kurevija, D Šojat, Z Bosnić, B Mujaj… - 2024 - preprints.org
Chronic diseases, such as type 2 diabetes (T2D), are difficult to manage because they
demand continuous therapeutic review and monitoring. Beyond achieving the target HbA1c …
demand continuous therapeutic review and monitoring. Beyond achieving the target HbA1c …
The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes …
Aim: We evaluated the safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and
glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for their use with other glucose …
glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for their use with other glucose …